Orforglipron
ATTAIN-2
Eli Lilly · Phase 3 · Completed · Enrollment 1613
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Placebo | 53 participants | 24 participants | 94 participants | n/r | 4 |
| 6 mg Orforglipron QD | 66 participants | 42 participants | 70 participants | n/r | 0 |
| 12 mg Orforglipron QD | 103 participants | 67 participants | 82 participants | n/r | 4 |
| 36 mg Orforglipron QD | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.